Article

Neoadjuvant hormones: 8-months regimen appears to be no better than3-month regimen

Eight months of neoadjuvant hormone therapy prior to radiation therapyappears to offer no significant advantage over the standard of 3 monthsof therapy, at least in low- and intermediate-risk prostate cancer patients.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.